EXELIXIS, INC. (EXEL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $59.01, EXELIXIS, INC. (EXEL) is priced for +1.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-26.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/EXEL

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.6% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=18)

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• One molecule carries this company: the 10-K states plainly that "Sales related to cabozantinib account for the majority of our revenues.", and United States net product sales of the cabozantinib franchise were $555.0 million in the first quarter of 2026 alone.
• The patent table is the risk register, and it is specific: the composition-of-matter patent covering cabozantinib expires in 2026, with the salt, formulation and method-of-treatment patents running out between 2030 and 2033, while generic filers including MSN, Teva, Cipla, Sun and Biocon have all served notice.
• The next hard date is December 3, 2026, the target action date for the FDA's review of zanzalintinib in previously treated metastatic colorectal cancer, and no revenue from that approval sits in the company's own 2026 guidance.

Bull Case

Most biotechnology companies never reach the stage Exelixis is at, and the ones that do rarely stay there. The label on this company is mature, and that word changes how every number in the file should be read. There is no cash runway question here, no dilution to fund the next trial, no binary event that decides whether payroll gets met. Operating profit was $170.9 million in 2023, $604.6 million in 2024 and $872.2 million in 2025, on total revenues that went from $1,830.2 million to $2,168.7 million to $2,320.1 million. A drug company that is profitable, growing, and funding its own pipeline out of product sales is being valued on a completely different set of questions than a clinical-stage one, and the main question is durability rather than survival.

What produces those profits is one of the more useful molecules in oncology. Cabozantinib is approved in the United States and, per the 10-K, in "68 other countries", across advanced renal cell carcinoma both alone and with Bristol-Myers Squibb's nivolumab, previously treated liver cancer, radioactive-iodine-refractory thyroid cancer, and pancreatic and extra-pancreatic neuroendocrine tumors. Each new indication is incremental volume on a manufacturing and sales base that is already paid for, which is why the cost of goods runs at a few percent of product sales rather than at the levels a hardware business would face. Ipsen and Takeda sell it outside the United States and paid $45.9 million of royalties in the March quarter.

The pipeline is where a mature single-product company either renews itself or does not, and this one is spending seriously on the attempt. Research and development ran $825.0 million in 2025 against $2,320.1 million of revenue. The lead asset, zanzalintinib, is described in the 10-K as "currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications". Seven pivotal studies are running or about to start, and Merck began a second phase 3 trial combining zanzalintinib with its own WELIREG in advanced kidney cancer in April 2026. A large partner funding a phase 3 with your compound is the closest thing to external validation the sector offers.

The balance sheet supports all of it without qualification. Cash, equivalents and marketable securities came to roughly 1.43 billion dollars at March 31, 2026, and the balance sheet carries no borrowings at all: the only long-dated obligation is the lease on the Alameda campus. That has let management do something unusual for a biotech, which is shrink itself. Diluted shares outstanding fell from 321.5 million in 2023 to 296.1 million in 2024 to 281.9 million in 2025, and to 267.3 million for the March 2026 quarter. Roughly $1,159.7 million has gone out under repurchase programs, and the board authorized a further $750 million in May 2026.

Compared against the profitable oncology and rare-disease names it sits with, the economics hold up. VRTX earns a 38.3% operating margin on revenue of 12.22 billion dollars and NBIX earns 25.4%, while BMRN manages 9.7% and ALKS 12.3%. Exelixis is at the upper end of that range on a fraction of the revenue base, which is what a single high-priced oral oncology drug with a built-out commercial organisation looks like when it is working.

Bear Case

Turn to the patent table in the 10-K. It is a short page and it is the most consequential thing in the entire filing. The composition-of-matter patent covering cabozantinib, number 7,579,473, expires in 2026. What stands between the franchise and generic entry after that is a stack of secondary patents on salt and polymorphic forms, formulations, and methods of treatment, expiring between 2030 and 2033. Secondary patents are a weaker fence than composition of matter, and the queue outside it is long: the company has received Paragraph IV certification notices from MSN, Teva, Cipla, Sun and Biocon on generic applications, and from Azurity and Handa on alternative-strength filings. In Europe, composition of matter runs to 2029 with supplementary protection.

That is the external variable with the most leverage on this thesis, and it is not the only one pointing the same direction. Cabozantinib is a small-molecule oral drug reimbursed heavily through Medicare Part D, which is precisely the category the Inflation Reduction Act aimed at. The 10-K describes the Medicare Drug Price Negotiation Program enabling the government "to assert control over the prices of certain single-source drugs and biotherapeutics reimbursed under Medicare Part B and Part D", with a small-biotech exception that shields qualifying drugs only through 2028. Between the patent clock and the negotiation clock, the two forces that could compress this franchise are both scheduled rather than speculative.

Now weigh that against how recent the profits are. Operating profit was $170.9 million as recently as 2023. The methods that average several years of results rather than annualizing the last twelve months land materially below the current price, and they are not being unfair; they are simply refusing to treat two good years as a level. A buyer today is paying for a profit base that has roughly quintupled in three years to be defended through a period when the legal protection around it is scheduled to weaken.

The replacement is real but unfinished. Zanzalintinib is under FDA review for one indication in colorectal cancer, with a target action date of December 3, 2026, and the company's own 2026 revenue guidance excludes any contribution from it. That is the correct way to guide and it is also the honest measure of where things stand: the successor product contributes nothing yet. Research and development spending of $825.0 million in 2025 buys a lot of shots, but the STELLAR-303 trial met one of its two primary endpoints rather than both, and the gap between a statistically significant overall-survival signal and a commercial franchise the size of cabozantinib is measured in years and several more readouts.

None of this threatens the company's existence. With roughly 1.43 billion dollars of cash and securities, no borrowings, and a share count that keeps falling, Exelixis can absorb a great deal of disappointment. The bear case is about what happens to a valuation built on the current profit base when the protection around that base runs down on a published schedule, and about the fact that the buyback, welcome as it is, does not extend a patent.

Valuation

Two families of method reach this price and two do not, and the split is informative rather than arbitrary. Peer multiples and the cash-flow-based approaches both land at or above where the stock trades. The book-value approaches and the no-growth earnings-power approaches land well below it. That is the ordinary signature of a company whose assets are legal and intangible rather than physical: there is almost nothing on the balance sheet to anchor an asset-based estimate, because the value is a patent estate and a sales force.

What the price actually assumes is modest, which is the surprise in the file. Working the current level backwards produces a requirement for operating profit to grow only around 3% a year over the next five years, a pace comfortably inside what this business has recently delivered. The market is not asking for heroics here. It is asking for the current franchise to hold roughly flat in real terms while the pipeline does whatever it does, and the whole investment question is whether the patent calendar permits that.

One method sharpens the same point from the other side. Rather than annualizing the most recent twelve months, it averages operating profit across five years and credits no growth at all. On that basis the price is well above what the method reaches, and the arithmetic behind it is visible in the filed statements: operating profit was $170.9 million in 2023, $604.6 million in 2024 and $872.2 million in 2025. Averaging that sequence is a way of asking whether the current level is the business or a moment in it.

The filing-sourced inputs are clean and worth stating exactly. Total revenues were $2,320.1 million for fiscal 2025, of which net product revenues were $2,122.8 million and collaboration revenues $197.3 million. Research and development ran $825.0 million and selling, general and administrative $518.7 million. In the March 2026 quarter, revenues were $610.8 million against $555.4 million a year earlier, and operating profit was $251.3 million against $186.9 million. Company guidance for fiscal 2026 puts total revenues in a band of 2,525 million to 2,625 million dollars, with research and development of $875 million to $925 million, and explicitly excludes any zanzalintinib contribution.

Against the peer set the profitability is at the strong end without the scale to match. VRTX runs a 38.3% operating margin on revenue of 12.22 billion dollars and REGN 24.3% on 14.92 billion dollars; NBIX earns 25.4% on a base closer to this company's own. The balance sheet is the cleanest part of the picture: roughly 1.43 billion dollars of cash and securities at the end of the March quarter, no borrowings, and a diluted share count that has fallen in each of the last three reported years. That combination means the downside here is not financial distress. It is the slower, more ordinary risk that a profitable single-product company runs out of patent before it runs out of pipeline.

Catalysts

December 3, 2026 is the date worth writing down. That is the target action date for the FDA's review of zanzalintinib, in combination with atezolizumab, for previously treated metastatic colorectal cancer, and it would be the first approval for a molecule the company intends to build its next franchise on. Management has kept every dollar of that potential launch out of its own 2026 revenue guidance, so an approval is upside to the published numbers rather than something already counted.

The rest of the year is unusually full of readouts. The company expects data from the STELLAR-303 and STELLAR-304 trials during 2026, continued enrollment in STELLAR-311, and initiation of STELLAR-316, alongside a newly started phase 2 study in recurrent meningioma. In April, collaborator Merck began LITESPARK-034, a second phase 3 pivotal trial combining zanzalintinib with WELIREG in advanced kidney cancer, and two further studies were announced on the same day as first quarter results: a planned phase 2 in lung cancer and an expansion cohort testing the compound with docetaxel in castration-resistant prostate cancer.

On the commercial and capital side the moves are steadier. First quarter revenues were $610.8 million, with cabozantinib franchise net product sales in the United States of $555.0 million and royalties from Ipsen and Takeda of $45.9 million, and reported diluted earnings were $0.79 a share. A United States list-price increase of 3.0% for CABOMETYX and COMETRIQ took effect on January 1, 2026 and is already inside guidance. The board authorized an additional $750 million of repurchases in May 2026, running to the end of 2027, with the prior program expected to finish that same month.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• REGN (REGENERON PHARMACEUTICALS, INC.)
• FY2025 10-K: …developed in collaboration with our collaborators) and the substantial competition they face, see also Part I, Item 1A. "Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - The commercial success of our products and product…
• FY2025 10-K: …are insufficient to protect our proprietary rights, our 54 Table of Contents business and competitive position will be harmed. "). Any future loss of market exclusivity for a product would likely negatively affect revenues from product sales of that product and thus our financial results and condition and could have…
• VRTX (VERTEX PHARMACEUTICALS INC / MA)
• FY2025 10-K: …protection and/or establish collaborative arrangements for research, development, manufacturing and commercialization. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in a larger concentration of resources among a smaller number of our competitors. Some of our…
• FY2025 10-K: …a particular disease typically increases over time and can result in slowed sales growth or reduced sales of our products in that therapeutic area. The development of new or improved treatment options could eliminate the use of our medicines or may limit the utility and application of ongoing clinical trials for our…
• BMRN (BioMarin Pharmaceutical Inc)
• FY2025 10-K: AZYME and is responsible for distributing, marketing, and selling ALDURAZYME to third parties. Competition Commercial Products The biopharmaceutical industry is rapidly evolving and highly competitive. Within the industry, there are many public and private companies, including pharmaceutical companies and…
• FY2025 10-K: …staff members market our products (other than ALDURAZYME). We believe that with moderate changes in 2026, the size of our sales force will be appropriate to effectively reach our target customers in markets where our products are directly marketed. The launch of any future products, if approved, or for the 9 sales…
• ALNY (ALNYLAM PHARMACEUTICALS, INC.)
• FY2025 10-K: …• patent position. Our competitors may develop or commercialize products with significant advantages over any products we or our collaborators develop based on any of the factors listed above or on other factors. In addition, our competitors may enter into collaborations with or receive funding from larger…
• FY2025 10-K: …the potential to become a leading therapy for ATTR amyloidosis and to significantly improve our gross margins on product sales and our non-GAAP operating income margin. Results of Operations The following table summarizes the results of our operations: Years Ended December 31, 2025 vs 2024 2024 vs 2023 (In thousands,…
• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …conflicts. General business and economic conditions that could affect our business, financial condition or results of operations include fluctuations in economic growth, inflation and interest rates, debt and equity capital markets, liquidity of the global financial markets, the availability and cost of credit,…
• FY2025 10-K: …immunological disorders. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief…
• BIIB (BIOGEN INC.)
• FY2025 10-K: …prioritize other opportunities in our pipeline. If we fail to compete effectively, our business and market position would suffer. The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and…
• FY2025 10-K: …regulatory pathways, including generic, prodrugs or biosimilar versions of our marketed products or competing products, including but not limited to, increased competition from TECFIDERA generic entrants and a biosimilar entrant of TYSABRI; • patent terms, patent term extensions, patent office actions and expected…
• ACAD (ACADIA PHARMACEUTICALS INC)
• FY2025 10-K: …we have a product to sell for the applicable disorder. Our competitors may also develop alternative therapies that could further limit the market for any drugs that we may develop. Many of our competitors are using technologies or methods different or similar to ours to identify and validate drug targets and to…
• FY2025 10-K: …marketing, and management personnel and for licenses to additional technologies. Our competitors, either alone or with their collaborators, may succeed in developing technologies or drugs that are more effective, safer, more affordable, or more easily administered than ours and may achieve patent protection or…
• ALKS (Alkermes plc.)
• FY2025 10-K: …which could materially adversely effect our business, financial condition, cash flows and results of operations. 44 Our success largely depends upon our ability to attract, recognize and retain key personnel. Our ability to compete and succeed in the highly competitive biopharmaceutical industry and in the disease…
• FY2025 10-K: …condition, cash flows and results of operations; • our success largely depends upon our ability to attract, recognize and retain key personnel, and the loss of key personnel may materially and adversely impact our business; • patent and other IP protection for our products is key to our business and our competitive…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.